One hundred and five sequential transjugular core liver biopsies (TJLBx) were performed in 101 patients with coagulopathy and/or ascites using the 19-gauge Quick-Core Biopsy (QCB) needle. Two-hundred and seventy-three cores were obtained in 295 passes (92. 5%). One-hundred and two of the 105 procedures (97.1%) led to a histopathologic diagnosis. One of the three nondiagnostic biopsies was done because of severe autolysis of the liver. There was one subcapsular hematoma, one hepatic arteriovenous fistula, and one liver capsular puncture. Two minor neck hematomas occurred. One death was reported (unrelated to the procedure). QCB needle TJLBx is an effective and relatively safe way to obtain core liver samples.
A 50-year-old patient with a history of hepatitis C was recently found to have multiple liver masses. Imaging showed several 3 cm lesions with classic hypervascularity in the arterial phase and washout in the venous phase compatible with hepatocellular carcinoma (HCC). Alpha-fetal protein was also elevated. The patient did not qualify for transplant due to the multiple numbers of lesions involving both lobes. The lesions were unable to be surgically resected and unable to be ablated.• Outside of systemic therapy, what are the types of locoregional therapy that are available? If the lesions are inoperable and also unable to be ablated, a form of transarterial therapy can be considered. This procedure utilizes transarterial technique for chemoinfusion, bland embolization, chemoembolization, and radioembolization.Transarterial chemoinfusion (aka hepatic artery infusion (HAI)) utilizes the drug's first-pass extraction rate pharmacokinetic principle. For example, floxuridine has a hepatic extraction rate of 95%, which significantly reduces the systemic toxicity. Recently, Okusaka et al. (2009) demonstrated that for inoperable HCC, HAI was as effective as transarterial chemoembolization. This randomized phase III prospective study with 161 patients showed there was no statistical difference of median overall survival time between chemoembolization group (646 days) versus HAI group (679 days) (P = 0.383). They concluded that by adding embolization, it did not increase survival over HAI in patients with HCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.